Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
InMode (Nasdaq: INMD) announced key leadership changes effective immediately. Dr. Shlomo Nass was appointed Chairman of the Board, succeeding retired chairman Dr. Michael Anghel. InMode also promoted Moshik Itzkovich, formerly Senior Vice President of Finance, to Chief Financial Officer, replacing Yair Malca, who will remain as a consultant through the Annual General Meeting to support a smooth transition.
InMode (NASDAQ: INMD) announced participation in two upcoming investor events. Management will join the Barclays Virtual West Coast Bus Trip on May 20, featuring a virtual investor bus tour.
The company will also attend the Jefferies Global Healthcare Conference in New York on June 3, with an in-person fireside chat at 12:45 pm ET and one-on-one meetings. A live webcast of the presentation will be available.
InMode (Nasdaq: INMD) reported Q1 2026 GAAP revenue of $82.0 million, a 5% increase versus Q1 2025, with GAAP net income of $11.6 million ($0.18 diluted) and GAAP gross margin of 75%. Cash, equivalents and short-term investments totaled $537.2 million as of March 31, 2026. Management completed repurchase of 2.55 million shares ($34.8 million) and announced a CFO transition and a board chair change. Full-year 2026 guidance: revenue $365–375 million, non-GAAP gross margin 74–76%, non-GAAP operating income $73–78 million, non-GAAP EPS $1.33–1.38.
InMode (Nasdaq: INMD) expects to report first quarter 2026 results before market open on May 6, 2026, and will hold a conference call at 8:30 a.m. ET that day. Management currently expects Q1 revenue $81.5M–$81.7M and non‑GAAP gross margin 75%–76%. The company reiterated FY2026 revenue guidance $365M–$375M. Results are preliminary and subject to final adjustments; the call will be webcast with a replay available through May 20, 2026, and on the investor site for 90 days.
InMode (Nasdaq: INMD) announced that CEO Moshe Mizrahy and CFO Yair Malca will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 11:00 AM Eastern Time. The session is a fireside chat moderated by Michael Matson.
A live webcast of the presentation will be available and InMode will hold virtual one-on-one investor meetings the same day; scheduling is via Needham representatives and additional event details are on the company's investor relations site.
InMode (Nasdaq: INMD) on March 13, 2026 authorized a new share repurchase program for up to approximately 10% of shares outstanding (about 6.38 million ordinary shares). The company said it repurchased roughly $127.4 million of shares in 2025 and expects to fund repurchases with available cash.
Repurchases may occur in the open market or by other permitted means, are subject to market and legal conditions, and the program may be modified, suspended, or discontinued at the company's discretion.
InMode (Nasdaq: INMD) will present at two investor conferences in March 2026: Barclays 28th Annual Global Healthcare Conference and Oppenheimer 36th Annual Healthcare MedTech & Services Conference.
Presenters: Yair Malca, CFO (Barclays); Moshe Mizrahy, CEO, and Yair Malca, CFO (Oppenheimer). Webcasts are scheduled for March 11 and March 16.
InMode (Nasdaq: INMD) announced that its Board's independent transaction committee has completed a review of proposals for a potential transaction and determined that none of the final proposals was adequate or in shareholders' best interests.
The Committee has discontinued the process; the company will continue to evaluate business and cash allocation strategies to enhance long-term shareholder value and does not intend further updates unless appropriate or required.
InMode (Nasdaq: INMD) reported Q4 2025 GAAP revenue of $103.9 million (+6% vs. Q4 2024) and full‑year 2025 revenue of $370.5 million (‑6% vs. 2024). GAAP net income was $27.0M in Q4 and $93.8M for FY 2025. Cash and marketable securities totaled $555.3M at year‑end. The company repurchased $127.4M of shares in 2025. Management expects 2026 revenue of $365M–$375M and non‑GAAP diluted EPS of $1.43–$1.48. Non‑GAAP measures exclude share‑based compensation and tax benefit adjustments.
InMode (Nasdaq: INMD) will participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT. Yair Malca, Chief Financial Officer, will host investor meetings on Wednesday, February 11, 2026. Interested investors should contact their BTIG salesperson to schedule a meeting and may visit InMode's investor relations site for event details.